{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:37:43Z","timestamp":1787938663030,"version":"build-2784847793"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sigurd and Elsa Golje Memorial Foundation","award":["LA2020-0016"],"award-info":[{"award-number":["LA2020-0016"]}]},{"name":"Sigurd and Elsa Golje Memorial Foundation","award":["LA2019-0084"],"award-info":[{"award-number":["LA2019-0084"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Corticosteroids appears to be beneficial for severe Mycoplasma pneumoniae pneumonia in children, but data in adults are limited. This study investigated effects of adjunctive corticosteroids in hypoxemic adults with M. pneumoniae pneumonia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults admitted 2013\u20132017 with verified M. pneumoniae pneumonia and hypoxemia (SpO2 &amp;lt; 93% or oxygen treatment) were included in a cohort. Treatment was defined as receipt of at least 1 glucocorticoid dose.<\/jats:p>\n                  <jats:p>Primary outcome was time to regression of hypoxemia, analyzed with a multivariable Cox regression. Secondary outcomes included fever duration, length of stay, and complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Corticosteroids were given to 31% (122\/388) during hypoxemia. Median age was 44 (interquartile range [IQR] 34\u201357) years. Median time to start of corticosteroid treatment was 1.9 (IQR 0.6\u20133.6) days from admission. Median cumulative dose was equivalent to 15 (IQR 10\u201319) mg betamethasone. Treatment duration was 5 (IQR 3\u20136) days. Patients treated with corticosteroids had more severe respiratory disease, longer symptom duration, and were more often treated with fluoroquinolones.<\/jats:p>\n                  <jats:p>Time to regression of hypoxemia (hazard ratio [HR] 0.92 [95% confidence interval {CI}: .72\u20131.19], P = .53) and length of stay (HR 0.91 [95% CI: .71\u20131.16], P = .44) were not significantly different between corticosteroid treated and controls. Corticosteroid treatment was associated to shorter fever duration (HR 1.44 [95% CI: 1.00\u20132.06], P = .046). Complications did not differ significantly between treatment groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Adjunctive corticosteroids were not associated with reduced time to regression of hypoxemia in adults with M. pneumoniae pneumonia. However, duration of fever was shorter and no increase in complications was seen.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae451","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T06:49:36Z","timestamp":1725518976000},"page":"454-460","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of Adjunctive Corticosteroid Treatment in Hypoxemic Adults Hospitalized for <i>Mycoplasma pneumoniae<\/i> Pneumonia: A Retrospective Cohort Study"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5965-6130","authenticated-orcid":false,"given":"Karl","family":"Hagman","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Sahlgrenska University Hospital , Gothenburg ,","place":["Sweden"]},{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Sk\u00e5ne University Hospital , Malm\u00f6 ,","place":["Sweden"]},{"name":"Department of Translational Medicine, Infectious Diseases Research Unit, Lund University , Malm\u00f6 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8539-9820","authenticated-orcid":false,"given":"Magnus","family":"Hedenstierna","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Danderyd Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Ursing","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Danderyd Hospital , Stockholm ,","place":["Sweden"]},{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"issue":"Suppl 1","key":"2025022409325661100_ciae451-B1","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1093\/clinids\/17.Supplement_1.S37","article-title":"Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients","volume":"17","author":"Foy","year":"1993","journal-title":"Clin Infect Dis"},{"key":"2025022409325661100_ciae451-B2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fmicb.2016.00157","article-title":"Mycoplasma pneumoniae epidemiology in England and Wales: a national perspective","volume":"7","author":"Brown","year":"2016","journal-title":"Front Microbiol"},{"issue":"Suppl 1","key":"2025022409325661100_ciae451-B3","first-page":"S32","article-title":"Clinical overview of typical Mycoplasma pneumoniae infections","volume":"17","author":"Clyde","year":"1993","journal-title":"Clin Infect Dis"},{"key":"2025022409325661100_ciae451-B4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3389\/fmicb.2014.00410","article-title":"Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications","volume":"5","author":"Saraya","year":"2014","journal-title":"Front Microbiol"},{"key":"2025022409325661100_ciae451-B5","doi-asserted-by":"crossref","first-page":"e20121","DOI":"10.1097\/MD.0000000000020121","article-title":"Efficacy and safety of azithromycin combined with glucocorticoid on refractory Mycoplasma pneumoniae pneumonia in children: a PRISMA-compliant systematic review and meta-analysis","volume":"99","author":"Qiu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2025022409325661100_ciae451-B6","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1002\/ppul.26592","article-title":"Corticosteroids for the treatment of respiratory infection by Mycoplasma pneumoniae in children: a cost-utility analysis","volume":"58","author":"Buendia","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2025022409325661100_ciae451-B7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/tropej\/fmu022","article-title":"Early treatment with corticosteroids in patients with Mycoplasma pneumoniae pneumonia: a randomized clinical trial","volume":"60","author":"Huang","year":"2014","journal-title":"J Trop Pediatr"},{"key":"2025022409325661100_ciae451-B8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/INF.0000000000002529","article-title":"Meta-analysis of the clinical efficacy and safety of high- and low-dose methylprednisolone in the treatment of children with severe Mycoplasma pneumoniae pneumonia","volume":"39","author":"Sun","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"2025022409325661100_ciae451-B9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.resinv.2017.11.005","article-title":"Recent trends in practice patterns and impact of corticosteroid use on pediatric Mycoplasma pneumoniae-related respiratory infections","volume":"56","author":"Okubo","year":"2018","journal-title":"Respir Investig"},{"key":"2025022409325661100_ciae451-B10","doi-asserted-by":"crossref","first-page":"566371","DOI":"10.3389\/fped.2020.566371","article-title":"Low-dose corticosteroid treatment in children with Mycoplasma pneumoniae pneumonia: a retrospective cohort study","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Pediatr"},{"key":"2025022409325661100_ciae451-B11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12890-017-0566-4","article-title":"Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia","volume":"17","author":"Tashiro","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2025022409325661100_ciae451-B12","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","article-title":"Hydrocortisone in severe community-acquired pneumonia","volume":"388","author":"Dequin","year":"2023","journal-title":"N Engl J Med"},{"key":"2025022409325661100_ciae451-B13","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/cid\/ciad496","article-title":"Efficacy and safety of corticosteroid therapy for community-acquired pneumonia: a meta-analysis and meta-regression of randomized, controlled trials","volume":"77","author":"Bergmann","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025022409325661100_ciae451-B14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1165\/rcmb.2017-0006OC","article-title":"The immunopathologic effects of Mycoplasma pneumoniae and community-acquired respiratory distress syndrome toxin: a primate model","volume":"58","author":"Maselli","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2025022409325661100_ciae451-B15","doi-asserted-by":"crossref","first-page":"1054788","DOI":"10.3389\/fimmu.2022.1054788","article-title":"The CARDS toxin of Mycoplasma pneumoniae induces a positive feedback loop of type 1 immune response","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"2025022409325661100_ciae451-B16","doi-asserted-by":"crossref","first-page":"e2220949","DOI":"10.1001\/jamanetworkopen.2022.20949","article-title":"Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections","volume":"5","author":"Kim","year":"2022","journal-title":"JAMA Network Open"},{"key":"2025022409325661100_ciae451-B17","first-page":"31374","article-title":"No detection of macrolide-resistant Mycoplasma pneumoniae from Swedish patients, 1996\u20132013","volume":"6","author":"Gullsby","year":"2016","journal-title":"Infect Ecol Epidemiol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae451\/59385602\/ciae451.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/2\/454\/59385602\/ciae451.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/2\/454\/59385602\/ciae451.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T09:35:16Z","timestamp":1740389716000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/2\/454\/7749266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,9,4]]},"published-print":{"date-parts":[[2025,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae451","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,15]]},"published":{"date-parts":[[2024,9,4]]}}}